SCHEMBL18668014

SCHEMBL18668014

c1ccc(-c2ccc(-c3nc(-c4ccccc4)nc(-c4ccc(-n5c6c7ccccc7ccc6c6c7ccccc7c7ccccc7c65)cc4)n3)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 3/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ATM Q13315 1/20 0.34
PDPK1 O15530 3/20 0.34
AVPR1A P37288 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HPRT1 P00492 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RXRA P19793 1/20 0.32
PDE6D O43924 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18668011 0.99 MAPT (0.39) MAPTNPC1LMNARECQLRAB9A
SCHEMBL23741632 0.94 MAPT (0.38) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18667554 0.93 HPRT1 (0.38) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18668015 0.93 CYP1A2 (0.37) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18667514 0.93 MAPT (0.40) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18667902 0.91 MAPT (0.41) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18667511 0.91 MAPT (0.41) MAPTNPC1LMNARECQLRAB9A
SCHEMBL19844122 0.91 MAPT (0.36) MAPTNPC1LMNARECQLRAB9A
SCHEMBL21863152 0.90 MAPT (0.45) MAPTNPC1LMNARECQLRAB9A
SCHEMBL12691002 0.90 NPC1 (0.37) MAPTNPC1LMNARECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421721-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2019-09-24 US disclosed
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2018-02-08 US disclosed
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2018-02-08 US disclosed
WO-2017047992-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421721-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 MAPT 1166/4885NPC1 4040/4885LMNA 3641/4885
US-20180037547-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 MAPT 1166/4885NPC1 4040/4885LMNA 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.